DOP2016000212A - Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados - Google Patents
Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionadosInfo
- Publication number
- DOP2016000212A DOP2016000212A DO2016000212A DO2016000212A DOP2016000212A DO P2016000212 A DOP2016000212 A DO P2016000212A DO 2016000212 A DO2016000212 A DO 2016000212A DO 2016000212 A DO2016000212 A DO 2016000212A DO P2016000212 A DOP2016000212 A DO P2016000212A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- dislipidemia
- gpr119
- obesity
- modulators
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS HETEROCÍCLICOS CONDENSADOS SUSTITUIDOS. LOS COMPUESTOS HETEROCÍCLICOS CONDENSADOS SUSTITUIDOS SON MODULADORES DE GPR119 Y SON ÚTILES PARA LA PREVENCIÓN Y/O EL TRATAMIENTO DE LA DIABETES, OBESIDAD, DISLIPIDEMIA Y TRASTORNOS RELACIONADOS. LA INVENCIÓN SE REFIERE ADEMÁS AL USO DE COMPUESTOS HETEROCÍCLICOS CONDENSADOS SUSTITUIDOS COMO INGREDIENTES ACTIVOS EN PRODUCTOS FARMACÉUTICOS, Y A COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14305494 | 2014-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2016000212A true DOP2016000212A (es) | 2016-11-15 |
Family
ID=50513859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2016000212A DOP2016000212A (es) | 2014-04-04 | 2016-08-15 | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados |
Country Status (21)
Country | Link |
---|---|
US (1) | US9758520B2 (es) |
EP (1) | EP3126336B1 (es) |
JP (1) | JP2017509679A (es) |
KR (1) | KR20160132885A (es) |
CN (1) | CN106164073A (es) |
AR (1) | AR099936A1 (es) |
AU (1) | AU2015239021A1 (es) |
CA (1) | CA2942753A1 (es) |
CL (1) | CL2016002497A1 (es) |
CR (1) | CR20160460A (es) |
DO (1) | DOP2016000212A (es) |
EA (1) | EA030410B1 (es) |
EC (1) | ECSP16078779A (es) |
IL (1) | IL248129A0 (es) |
MA (1) | MA39346B1 (es) |
MX (1) | MX2016013033A (es) |
PE (1) | PE20161378A1 (es) |
PH (1) | PH12016501619A1 (es) |
SG (1) | SG11201606758SA (es) |
TW (1) | TW201625605A (es) |
WO (1) | WO2015150564A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR099936A1 (es) | 2014-04-04 | 2016-08-31 | Sanofi Sa | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados |
CA2943011A1 (en) | 2014-04-04 | 2015-10-08 | H. Lundbeck A/S | Halogenated quinazolin-thf-amines as pde1 inhibitors |
AR110988A1 (es) | 2017-02-21 | 2019-05-22 | Sanofi Sa | Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados |
WO2019043635A1 (en) | 2017-09-01 | 2019-03-07 | Richter Gedeon Nyrt. | COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE |
MX2020012965A (es) * | 2018-05-31 | 2021-02-16 | Hua Medicine Shanghai Ltd | Combinacion, composicion y preparacion de compuesto farmaceutico que comprende activador de glucocinasa e inhibidor de dpp-iv, metodo de preparacion y uso del mismo. |
KR102131359B1 (ko) * | 2018-09-07 | 2020-07-07 | 오토텔릭바이오 주식회사 | 안정성이 향상된 의약 조성물 |
US20220257624A1 (en) * | 2019-05-31 | 2022-08-18 | Avolynt | Compositions and methods for treating metabolic disease |
MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05013756A (es) * | 2003-06-18 | 2006-03-08 | Pfizer Prod Inc | Piperazinil-ariloxi y piperazinil-heteroariloxi-n-aril-lactamas novedosas. |
EA015675B1 (ru) * | 2006-04-21 | 2011-10-31 | Эли Лилли Энд Компани | Производные циклогексилпиразол-лактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1 |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
BR112012029395A2 (pt) * | 2010-05-17 | 2016-07-26 | Array Biopharma Inc | lactamas piperdinil-substituídas como moduladores de gpr119 |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
EP2616074A1 (en) | 2010-09-17 | 2013-07-24 | Array Biopharma, Inc. | Piperidinyl-substituted lactams as gpr119 modulators |
WO2013070463A2 (en) | 2011-11-11 | 2013-05-16 | Glaxosmithkline Llc | Treatment of blood lipid abnormalities and other conditions |
AR099936A1 (es) | 2014-04-04 | 2016-08-31 | Sanofi Sa | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados |
-
2015
- 2015-04-01 AR ARP150100989A patent/AR099936A1/es unknown
- 2015-04-01 TW TW104110619A patent/TW201625605A/zh unknown
- 2015-04-02 EA EA201692008A patent/EA030410B1/ru not_active IP Right Cessation
- 2015-04-02 PE PE2016001909A patent/PE20161378A1/es not_active Application Discontinuation
- 2015-04-02 JP JP2016560725A patent/JP2017509679A/ja not_active Abandoned
- 2015-04-02 MX MX2016013033A patent/MX2016013033A/es unknown
- 2015-04-02 MA MA39346A patent/MA39346B1/fr unknown
- 2015-04-02 WO PCT/EP2015/057414 patent/WO2015150564A1/en active Application Filing
- 2015-04-02 CR CR20160460A patent/CR20160460A/es unknown
- 2015-04-02 KR KR1020167026911A patent/KR20160132885A/ko unknown
- 2015-04-02 CA CA2942753A patent/CA2942753A1/en not_active Abandoned
- 2015-04-02 SG SG11201606758SA patent/SG11201606758SA/en unknown
- 2015-04-02 AU AU2015239021A patent/AU2015239021A1/en not_active Abandoned
- 2015-04-02 CN CN201580017438.3A patent/CN106164073A/zh active Pending
- 2015-04-02 EP EP15713528.6A patent/EP3126336B1/en active Active
-
2016
- 2016-08-15 PH PH12016501619A patent/PH12016501619A1/en unknown
- 2016-08-15 DO DO2016000212A patent/DOP2016000212A/es unknown
- 2016-09-29 IL IL248129A patent/IL248129A0/en unknown
- 2016-09-30 CL CL2016002497A patent/CL2016002497A1/es unknown
- 2016-10-03 US US15/284,213 patent/US9758520B2/en not_active Expired - Fee Related
- 2016-10-04 EC ECIEPI201678779A patent/ECSP16078779A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3126336B1 (en) | 2018-12-05 |
US20170022198A1 (en) | 2017-01-26 |
EA201692008A1 (ru) | 2017-02-28 |
CR20160460A (es) | 2017-02-21 |
JP2017509679A (ja) | 2017-04-06 |
WO2015150564A1 (en) | 2015-10-08 |
CA2942753A1 (en) | 2015-10-08 |
TW201625605A (zh) | 2016-07-16 |
CL2016002497A1 (es) | 2017-03-31 |
EP3126336A1 (en) | 2017-02-08 |
CN106164073A (zh) | 2016-11-23 |
ECSP16078779A (es) | 2017-02-24 |
MX2016013033A (es) | 2017-01-09 |
AU2015239021A1 (en) | 2016-10-13 |
AR099936A1 (es) | 2016-08-31 |
SG11201606758SA (en) | 2016-09-29 |
KR20160132885A (ko) | 2016-11-21 |
PE20161378A1 (es) | 2016-12-26 |
EA030410B1 (ru) | 2018-07-31 |
MA39346B1 (fr) | 2019-03-29 |
US9758520B2 (en) | 2017-09-12 |
IL248129A0 (en) | 2016-11-30 |
PH12016501619A1 (en) | 2017-02-06 |
MA39346A1 (fr) | 2017-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2016000226A (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
DOP2016000212A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
CL2018000542A1 (es) | Nuevos derivados de fenoximetilo. | |
SV2017005426A (es) | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos | |
CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
GT201600215A (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
CL2018003135A1 (es) | Derivados aromáticos de sulfonamida. | |
BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
CR20150326A (es) | Inhibidores de autotaxina | |
EA201791310A1 (ru) | Химерные антигенные рецепторы к bcma | |
CL2015003314A1 (es) | Inhibidores de acc y usos de los mismos | |
DOP2015000274A (es) | Compuestos químicos | |
CL2018002718A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
CL2018002758A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue. | |
CL2015003315A1 (es) | Inhibidores de acc y usos de los mismos | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
UY35073A (es) | Derivados de pirrolidinona como moduladores de GPR119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados. | |
UY36340A (es) | Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue | |
UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
CL2017000136A1 (es) | Composiciones de azúcar para la formación de comprimidos por compresión directa | |
CR20160433A (es) | Nuevos compuestos | |
EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
CL2015000615A1 (es) | Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau. | |
DOP2016000312A (es) | Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2 |